Revenue
2019
2020
2021
2022
2023
2024
2025
GeneDx Holdings Corp. (WGS)
Price$85.71Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $427.5M | $305.4M | $202.6M | $234.7M | $212.2M | $179.3M | $196.2M |
| Gross profit | $298.2M | $194.4M | $90.0M | −$26.8M | −$16.6M | $4.0M | $82.8M |
| Gross margin | 69.74% | 63.64% | 44.43% | −11.40% | −7.82% | 2.25% | 42.20% |
| Research & development | $72.0M | $45.7M | $58.3M | $86.2M | $105.2M | $72.7M | $34.9M |
| Operating expenses | $311.3M | $217.6M | $270.6M | $640.9M | $429.5M | $4.2M | $113.2M |
| Operating income | −$13.1M | −$23.2M | −$180.6M | −$667.7M | −$446.1M | −$206,195 | −$30.4M |
| Operating margin | −3.06% | −7.60% | −89.15% | −284.48% | −210.25% | −0.11% | −15.50% |
| EBITDA | −$3.5M | −$15.3M | −$160.9M | −$617.7M | −$424.3M | $11.5M | −$24.0M |
| EBITDA margin | −0.81% | −5.01% | −79.43% | −263.17% | −199.98% | 6.43% | −12.24% |
| Net income | −$21.0M | −$52.3M | −$175.8M | −$549.0M | −$245.4M | −$241.3M | −$29.7M |
| Net profit margin | −4.92% | −17.12% | −86.77% | −233.91% | −115.64% | −134.58% | −15.14% |
| Basic EPSper basic share | -$0.73 | -$1.94 | -$7.23 | -$53.63 | -$75.67 | -$1,567,866.67 | -$8,801,866.67 |
| Diluted EPSper diluted share | -$0.73 | -$1.94 | -$7.23 | -$53.63 | -$75.67 | -$1,567,866.67 | -$8,801,866.67 |
Owners
Reported shareholders
16.05%of listed shares
Corvex Management LP4.78M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Corvex Management LP | 16.05%4.78M shares |
Casdin Eli | ≈13.70%4.08M shares |
Casdin Capital, LLC | 12.44%3.71M shares |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI / MOUNT SINAI HEALTH SYSTEM, INC. | ≈9.13%2.72M shares |
OPKO HEALTH, INC. | ≈8.88%2.65M shares |
BlackRock, Inc. | 5.73%1.71M shares |
GOLDMAN SACHS GROUP INC | 5.60%1.67M shares |
ARK Investment Management LLC | 5.40%1.61M shares |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 4.70%1.4M shares |
MORGAN STANLEY | 3.32%988.3K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.95%879K shares |
CITADEL ADVISORS LLC | 2.90%865.46K shares |
First Light Asset Management, LLC | 2.63%783.92K shares |
Deep Track Capital, LP | 2.35%700K shares |
Sumitomo Mitsui Trust Group, Inc. | 2.24%666.58K shares |
Amova Asset Management Americas, Inc. | 2.24%666.58K shares |
Assenagon Asset Management S.A. | 2.04%606.87K shares |
Zweig-DiMenna Associates LLC | 1.92%571.95K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.85%552.13K shares |
STATE STREET CORP | 1.77%527.82K shares |
Percentages use 29.8M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 | Feeley KevinCHIEF FINANCIAL OFFICER | SellClass A Common Stock | 863 | $61.50 | $53.1K | 40.0K |
| Jun 16, 2026Form 4 | Feeley KevinCHIEF FINANCIAL OFFICER | SellClass A Common Stock | 2.1K | $60.83 | $128.1K | 40.8K |
| Jun 16, 2026Form 4 | Feeley KevinCHIEF FINANCIAL OFFICER | SellClass A Common Stock | 760 | $59.75 | $45.4K | 42.9K |
| Jun 16, 2026Form 4 | Stueland KatherineCHIEF EXECUTIVE OFFICER | SellClass A Common Stock | 2.4K | $61.50 | $149.4K | 104.4K |
| Jun 16, 2026Form 4 | Stueland KatherineCHIEF EXECUTIVE OFFICER | SellClass A Common Stock | 5.9K | $60.83 | $360.8K | 106.8K |